Zacks: AEterna Zentaris Inc. (AEZS) Given $5.50 Average Target Price by Analysts

AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) has been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports.

Analysts have set a 12-month consensus price objective of $5.50 for the company and are forecasting that the company will post $0.04 EPS for the current quarter, according to Zacks. Zacks has also given AEterna Zentaris an industry rank of 77 out of 255 based on the ratings given to its competitors.

Several equities research analysts have weighed in on AEZS shares. ValuEngine raised AEterna Zentaris from a “hold” rating to a “buy” rating in a research report on Saturday, February 2nd. HC Wainwright reissued a “buy” rating on shares of AEterna Zentaris in a report on Thursday, January 17th. Finally, Zacks Investment Research raised AEterna Zentaris from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a report on Monday, March 18th.

NASDAQ AEZS traded down $0.36 during trading hours on Wednesday, hitting $3.62. The company had a trading volume of 329,400 shares, compared to its average volume of 323,970. AEterna Zentaris has a fifty-two week low of $1.29 and a fifty-two week high of $5.57. The firm has a market capitalization of $62.97 million, a PE ratio of 14.48 and a beta of 1.25.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last issued its earnings results on Tuesday, March 26th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.12). AEterna Zentaris had a return on equity of 55.49% and a net margin of 15.67%. The company had revenue of $1.40 million during the quarter, compared to analyst estimates of $0.25 million. On average, equities research analysts predict that AEterna Zentaris will post 2.25 earnings per share for the current year.

Several institutional investors and hedge funds have recently modified their holdings of AEZS. Acadian Asset Management LLC increased its holdings in shares of AEterna Zentaris by 27.2% during the fourth quarter. Acadian Asset Management LLC now owns 45,049 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 9,640 shares during the period. O Shaughnessy Asset Management LLC acquired a new position in shares of AEterna Zentaris during the fourth quarter valued at $66,000. Jane Street Group LLC acquired a new position in shares of AEterna Zentaris during the fourth quarter valued at $30,000. Finally, Virtu Financial LLC acquired a new position in shares of AEterna Zentaris during the first quarter valued at $179,000. 15.55% of the stock is currently owned by institutional investors.

AEterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.

Featured Article: Calculating net profit and net profit margin ratio

Get a free copy of the Zacks research report on AEterna Zentaris (AEZS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.